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EDITORIAL
How do placebos work?
Fabrizio Benedetti a,b, Alessandro Piedimonte a and Elisa Frisaldi a
aDepartment of Neuroscience, University of Turin Medical School, Turin, Italy; bPlateau Rosà Laboratories, Plateau Rosà, Italy/Switzerland
Clinical trials of post-traumatic stress disorder (PTSD)
show a high rate of placebo response, ranging from 19%
to 62% (Ipser & Stein, 2012; Kelmendi et al., 2016; Sher,
2004). Despite these placebo responses across a number
of clinical trials, nothing is known about their underlying
mechanisms. In fact, the clinical trial setting does not
allow us to differentiate between placebo effects due to
psychological factors such as patients’ expectations and
other phenomena such as spontaneous remission and
regression to the mean. The recent explosion of placebo
research and the shift in conceptualization of the placebo
effect in several medical conditions, such as pain and
motor disorders, makes us understand that their psycho-
logical and neurobiological underpinnings can be inves-
tigated in some detail. Indeed, what we have learned over
the past few years is that different brain mechanisms are
at work during the placebo response (Benedetti,
Amanzio, Rosato, & Blanchard, 2011; Benedetti,
Carlino, & Piedimonte, 2016; Wager & Atlas, 2015).
A placebo is usually defined as an inert substance with
no pharmacological action, or as a sham physical inter-
vention, although this definition is not complete, as
placebos are made of many things, such as words, rituals,
symbols, and meanings. Therefore, a placebo is not the
fake treatment per se, be it pharmacological or not, but
rather its administration within a complex psychosocial
context. Indeed, a placebo is the whole ritual of the
therapeutic act (Benedetti, 2014). The confusion about
the words placebo and placebo effect comes from the
different usage that they have for the clinical triallist and
the neuroscientist/psychologist. The former is interested
in any improvement that may take place in the group of
patients who take the inert substance, and this improve-
ment can be due to plenty of factors, such as spontaneous
remission, regression to the mean, and patient’s expecta-
tions of benefit. By contrast, the neuroscientist is only
interested in the improvement that derives from the
patient’s expectations, namely, an active process occur-
ring in the patient’s brain. Clinical trials are only aimed at
establishing whether the patients who take the true treat-
ment are better off than those who take the placebo,
whereas the neurosciences want to understand what is
going on in the patient’s brain when a placebo is given,
i.e. when a therapeutic ritual is performed. By using this
neuroscientific approach, the placebo effect represents an
excellent model to understand how the human brain
works (Benedetti, 2014; Wager & Atlas, 2015) and may
have profound implications for both medical practice
and clinical trials (Benedetti et al., 2016).
One of the most interesting and challenging
aspects of placebo research is related to the emerging
concept that placebos activate the same biochemical
pathways that are activated by drugs (Benedetti, 2014;
Benedetti et al., 2016), which represents quite an
interesting challenge from both an evolutionary and
a neurobiological perspective. Humans are endowed
with endogenous systems that can be activated by
verbally induced positive expectations, therapeutic
rituals, healing symbols, and social interactions, and
these systems include both endogenous opioids and
endocannabinoids in placebo analgesia (Benedetti
et al., 2011) and dopamine in Parkinson-related pla-
cebo responses (de la Fuente-Fernández et al., 2001).
When morphine is administered, it binds to opioid
receptors and inhibits pain transmission, but at the
same time the ritual of its administration induces the
activation of the same opioid receptors, involving a
descending pain modulating network that goes from
the cortex down to the spinal cord (Eippert, Bingel,
et al., 2009; Eippert, Finsterbusch, Bingel, & Büchel,
2009). Similarly, when an anti-Parkinson dopaminer-
gic drug is given it stimulates dopamine receptors,
but at the same time the ritual of its administration
activates the same dopamine receptors (de la Fuente-
Fernández et al., 2001), along with substantial
changes in neuronal activity in the basal ganglia
(Benedetti et al., 2004). More recent findings indicate
that the cyclooxygenase pathway can be affected by
placebos as well (Benedetti, Durando, & Vighetti,
2014), thus suggesting an intricate set of mechanisms,
including enzymatic activity, that can be activated by
psychosocial stimuli, such as patients’ expectations of
improvement and different therapeutic rituals.
It goes without saying that clear-cut differences
between placebo and drugs do exist (Benedetti et al.,
2016). First, as far as we know today, the duration of
the effect of a drug is longer than that of a placebo. For
example, the effect of the powerful anti-Parkinson drug
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apomorphine lasts on average much longer than a pla-
cebo. The mean duration of apomorphine is around
90 min, whereas the mean duration of the placebo effect
is about 30 min. Secondly, the variability of the response
is different, such that the clinical response is much more
variable after placebo administration than after apomor-
phine. As far as the magnitude of the response is con-
cerned, the effect following placebo administration can
be as large as the effect following drug administration.
For example, some good placebo responders may show a
reduction in the Unified Parkinson’s Disease Rating
Scale (UPDRS) of up to 50%, as also occurs for anti-
Parkinson drugs. The placebo effect can be even larger in
pain, where pain reduction can be of 5–6 points on a
scale ranging from 0 = no pain to 10 = unbearable pain,
as occurs in irritable bowel syndrome, where the analge-
sic response to a placebo has been found in a study to be
even larger than that to lidocaine (Vase, Robinson,
Verne, & Price, 2003). However, it is important to
point out that only a small percentage of placebo respon-
ders may show such huge effects.
A crucial point in placebo research is the under-
standing of why some people respond whereas others
do not. Different studies have addressed this impor-
tant point and now this approach is paying dividends
and bodes well for the future. Neuroimaging research
has shown that prefrontal circuitry is always involved
in placebo analgesia, in studies on chronic back pain
(Hashmi et al., 2012), fibromyalgia (Schmidt-Wilcke
et al., 2014), and chronic knee osteoarthritis (OA)
(Tétreault et al., 2016). The right midfrontal gyrus
(r-MFG) connectivity was specifically identified as a
biomarker that can predict the placebo response in
patients affected by OA (Tétreault et al., 2016).
Activity in the r-MFG was observed to be related to
decision making, memory, and planning processes,
thus supporting the idea that placebo analgesia is
driven by a complex top–down modulation. The
amygdala, nucleus accumbens (NAc), and ventral
striatum (VS) were also found to be regions closely
connected to the medial prefrontal circuitry. Placebo
analgesic treatments reliably reduce activity in the
amygdala and increase activity in the NAc-VS region
(Atlas & Wager, 2014). In particular, interindividual
differences in NAc-VS seem to be important for
identifying placebo responders and non-responders.
Indeed, strong placebo analgesic effects are predicted
by NAc-VS activity, including stronger placebo-
related opioid and functional magnetic resonance
imaging (fMRI) activity responses during pain,
increased grey matter volume, and stronger fMRI
responses in a reward pursuit task unrelated to pain
(Wager & Atlas, 2015).
Beside these advances in neuroimaging, the pharma-
cological experimental approach has shown that placebo
analgesic effects can be boosted using both vasopressin
and oxytocin agonists. In particular, a randomized trial
on healthy participants showed that vasopressin increases
placebo analgesia significantly compared to no treatment,
oxytocin, and saline, and these effects were found only in
women.Moreover, women with both lower dispositional
anxiety and cortisol levels showed the largest vasopressin-
inducedmodulation of placebo effects, suggesting amod-
erating interplay between pre-existing psychological fac-
tors and cortisol changes (Colloca, Pine, Ernst, Miller, &
Grillon, 2016).
Personality traits also contribute towards explaining a
substantial proportion of the variance in placebo analge-
sic effects; placebo effects have been found to be related to
optimism, suggestibility, empathy, and neuroticism,
whereas nocebo effects have been linked to pessimism,
anxiety, and catastrophizing (Corsi & Colloca, 2017).
Attempts to describe the placebo responder or non-
responder through a single personality trait may be limit-
ing and, indeed, a transactional model of placebo
responding, in which dispositional characteristics dyna-
mically interact with environmental contingencies, was
presented in 2015 (Darragh, Booth, & Consedine, 2015).
The overlaps among the personality traits identified so far
suggest that placebo responsiveness could be conceptua-
lized in terms of a two-faceted construct consisting of an
inward and an outward orientation. Personswith ‘inward
orientation’ show a tendency to have an internal focus, or
the ability to respond to suggestions regarding internal
experience, whereas persons with ‘outward orientation’
are pervious to external inputs. Absorption, suggestibility,
and acquiescence are personality traits that can be
included in the first facet of placebo responsiveness,
whereas resiliency, altruism, straightforwardness, opti-
mism, extraversion, and dopamine-related traits belong
to the second facet of placebo responsiveness. According
to this transactional model, when a match between the
type of individual and the nature of the contextual cues is
missing, responding may not arise. Consequently, health
practitioners could maximize the placebo component of
any treatment or increase the chance of responding to
treatment by tailoring clinical approaches based on how
certain individuals respond to contextual treatment. In a
recent experimental model of conditioning and heat
thermal painful stimulation, the potential advantage of
considering several personality factors was confirmed
(Corsi & Colloca, 2017). Moreover, it was shown for the
first time that expectations predict placebo and nocebo
effects independently of personality factors. In fact,
expectations were found to highly correlate with placebo
and nocebo effects, whereas psychological factors per se
did not influence levels of expectation of either reduction
or increase in pain.
In light of this new knowledge about placebo effects,
the crucial question is related to where (in which medical
condition), when (in which circumstance, e.g. at home or
in the hospital), and how (which mechanisms) placebos
work. Accordingly, PTSD represents a neuropsychiatric
disorder worthy of scientific investigation, from both a
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psychological and a neurobiological perspective. To do
this, we should disentangle patients’ expectations from
spontaneous remission and regression to the mean in
well-conceived and well-designed PTSD clinical trials.
Once the psychological component of placebo treatments
for PTSD has been identified and well described, the
psychobiological underpinnings should be investigated.
For example, neuroscientific research should be aimed at
assessing whether some endogenous systems, such as
opioids and/or cannabinoids, are involved in the placebo
response of PTSD.
Therefore, we need to change our perspective about
placebo effects and conceptualize them in a different way,
so that they can be considered as phenomena worthy of
scientific inquiry.Abetter understanding ofwhere,when,
and how placebos work represents an important chal-
lenge for future research, which will surely lead to better
medical practice and better interpretation of clinical
trials. As we know virtually nothing about placebo effects
in PTSD, this neuropsychiatric condition can be an excel-
lent model to unravel new mechanisms and to answer
some unanswered questions. The crucial starting point is
the understanding of the biological underpinnings. We
believe that medical practice and clinical trials, as well as
human biology and neuroscience, will benefit from this
new knowledge.
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